Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

@article{Kempf2004IncidenceOR,
  title={Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.},
  author={D. Kempf and M. King and B. Bernstein and P. Cernohous and E. Bauer and J. Moseley and K. Gu and A. Hsu and S. Brun and E. Sun},
  journal={The Journal of infectious diseases},
  year={2004},
  volume={189 1},
  pages={
          51-60
        }
}
  • D. Kempf, M. King, +7 authors E. Sun
  • Published 2004
  • Medicine
  • The Journal of infectious diseases
    • Study M98-863 was a double-blind, randomized, phase 3 study that compared lopinavir/ritonavir with nelfinavir, each coadministered with stavudine and lamivudine, in 653 antiretroviral therapy-naive human immunodeficiency virus (HIV) type 1-infected subjects. The incidence of HIV drug resistance was analyzed using baseline and rebound virus isolates from subjects with plasma HIV RNA >400 copies/mL from weeks 24 to 108 of therapy. No evidence of genotypic or phenotypic resistance to lopinavir… CONTINUE READING
    View on PubMed
    academic.oup.com
    219 Citations
    Highly Influential Citations
    11
    Background Citations
    67
    Methods Citations
    6
    Results Citations
    12
    219 Citations
    Citation Type

    Citation Type

    Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy
    • 59
    • PDF
    The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
    • 351
    Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
    • 15
    Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients
    • 153
    Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.
    • 98
    • PDF
    Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
    • 39
    • PDF
    Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
    • 5
    • PDF
    Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    • 26
    Efficacy and Tolerability of a Nucleoside Reverse Transcriptase Inhibitor-Sparing Combination of Lopinavir/Ritonavir and Efavirenz in HIV-1-Infected Patients
    • 34
    Virologic Failure in Therapy-Naïve Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope
    • 31
    • PDF

    References

    SHOWING 1-10 OF 38 REFERENCES
    Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    • 652
    ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
    • 242
    Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
    • 112
    Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
    • 146
    • PDF
    Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study)
    • 65
    Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.
    • 27
    • PDF
    Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
    • 507
    • PDF
    Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.
    • 396
    • PDF
    Nelfinavir: an update on its use in HIV infection.
    • 115
    Virologic Rebound on HAART in the Context of Low Treatment Adherence Is Associated With a Low Prevalence of Antiretroviral Drug Resistance
    • 74